Cancers · 2018 · 18 citations · 43 references
MedicineCancer BiologyOncologyDrug DiscoveryMolecular OncologyTranslational OncologyBiomarker ValidationCancer BiomarkersCancer GenomicsCancer ImmunotherapyLung CancerMolecular Tumor ProfilingBiobanking For Genomic MedicineCancer Genomic Biomarker DiscoveryCancer Genomics DatabasesClinical Data ValidationClinical Data WarehousesSomatic Genomic Alterations
Lung cancer is the major cause of death from cancer in the world and its incidence is increasing in women. Despite the progress made in developing immunotherapies and therapies targeting genomic alterations, improvement in the survival rate of advanced stages or metastatic patients remains low. Thus, urgent development of effective therapeutic molecules is needed. The discovery of novel therapeutic targets and their validation requires high quality biological material and associated clinical data. With this aim, we established a biobank dedicated to lung cancers. We describe here our strategy and the indicators used and, through an overall assessment, present the strengths, weaknesses, opportunities and associated risks of this biobank.
43
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text
Marie-Pierre Puisségur, Nathalie M. Mazure, Thomas Bertero et al. · Cell Death and Differentiation · 2010 · 414 citations · Full text
Medicine, Cancer Biology, Oncology +17
Véronique Hofman, Marius Ilié, Élodie Long-Mira et al. · International Journal of Cancer · 2010 · 301 citations · Full text